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HTake home messages
 To understand the main interplay between coagulation system and inﬂammation and to recognize the key invasive infectious
agents causing typical abnormalities in activation of blood platelets, coagulation and ﬁbrinolysis.
 To capture, monitor and follow-up the clinical and laboratory phenotype and the management related to the pathophysiology of
inﬂammation.he
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S9Introduction Current state of the artInﬂammation induced by infection results in local tissue damaged
followed by systemic endothelial injury, adhesion of platelets and
activation of the coagulation cascade. In addition, during infection
and inﬂammation the local control of coagulation fails, triggering
the vicious circle of coagulation activating inﬂammation and vice
versa. The hemostatic system represents the ﬁrst and the most
immediate element, programming tissue response to injury and
continuum of inﬂammation, angiogenesis, stromal recruitment
and repair.
∗1 Endothelium is under continuous interphase with
blood ﬂow. From blood the pathogens and inﬂammatory
mediators invade organ(s), causing vascular damage, micro-
thrombi and multi(organ) failure (eg, sepsis).
∗2 Upon escape of the
local regulation of coagulation, typical clinical entities include
thrombotic microangiopathy (hemolytic anemia, thrombocytope-
nia and microthrombi), complement (membrane attack complex)
interplay and disseminated intravascular coagulation (DIC).
∗3,4
Inﬂammation can inﬂuence all the three phases of hemostasis and
their regulation: (1) megakaryocytes and platelets, (2) coagulation
and (3) ﬁbrinolysis (Fig. 1). This short review will provide
examples, and some clinical management opportunities in these
three phases.authors have indicated they have no potential conﬂicts of interest to disclose.
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coagulation disorders
During bacterial infection, dual activation of platelets and
macrophages can eradicate bacteria in liver.5 Strong leukocyte-
derived proteolytic enzymes will cleave the anticoagulant and
protective endothelial layer of glycosaminoglycans (GAG, ie,
heparan sulfate, perlecans and syndecans), exposing von
Willebrand factor (VWF), collagen and laminin to trigger platelet
deposition, thrombin and ﬁbrin formation (Fig. 1).6
Endothelial cells will constitutively secrete VWF, and VWF-size
cleaving and controlling ADAMTS-13 enzyme to maintain VWF
homeostasis. Infection may consume ADAMTS-13 or lead to
antibody formation to exhaust or inactivate its capacity. This can
result in the development of thrombotic thrombocytopenic
purpura (TTP), or hemolytic uremic syndromeHUS or atypical,
aHUS causing, thrombosis formation in the microvasculature
(brain, kidneys) due to platelet- and VWF-rich deposition and
complement activation.7 Platelets can also bind to endothelial
derived-VWF and generated ﬁbrin on the endothelium (throm-
bocytopenia, “consumption”). Thrombocytopenia, during DIC,
may refer to reduced survival in association with severely ill
infected patients. The timely therapy of the infection and/or
inﬂammation, including regulation of coagulation may break this
vicious loop.
∗8 The main tools to limit excessive coagulation in
treating and preventing thrombosis include mainly acetylsalicylic
acid, or low-molecular weight heparin (LMWH). If a coagulation
defect, that is, low antithrombin is noted and corrected early
the balance of coagulation will tilt to a more physiological
position.
∗8,9
The role of megakaryocytes, platelets and thrombin in
infection and inﬂammation
While the hemostatic roles of platelets are well recognized,
emerging data demonstrate that megakaryocytes and platelets
possess diverse and dynamic functions that also mediateEducational Updates in Hematology Book | 2019; 3(S2) | 95 |
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Figure 1. Coagulation targets of some pathogen as examples. Coagulation occurs sequentially: (A) platelet adhesion and activation, (B)
thrombin generation and ﬁbrin formation and (C) degradation of ﬁbrin by ﬁbrinolysis. Some infectious agents at each step are presented as
examples. CMV = cytomegalovirus, EHEC = Entero Hemolytic Escherichia Coli, HCV = hepatitis C virus, HIV= human immunodeﬁciency virus,
LPS = lipopolysaccharide, TF= tissue factor.
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infection processes result in thrombocytopenia due to enhanced
destruction of megakaryocytes and platelets.13–15
However, megakaryocytes and platelets possess a multitude of
innate immune tools, including toll-like receptors, to recognize
pathogens, and Fc receptors, which recognize immune com-
plexes.10 In addition, platelets contain many antimicrobial agents,
including antimicrobial peptides and beta-defensins, which
directly act on bacterial pathogens.10,12,16 Platelets also release
chemokines such as platelet factor 4, RANTES and b-thrombo-
globulin, which increase leukocyte recruitment and survival
during viral infections, and can reduce HIV infection by directly
interacting with the viral envelope.17–19
Recently, megakaryocytes have been shown to play signiﬁcant
roles in ﬁghting infections. For example, megakaryocytes possess
major histocompatibility complex (MHC) I and are capable of
endocytosing endogenous antigen.20 Upon processing the antigen
through the proteasome, megakaryocytes can present antigens in
anMHC-I dependent manner to activate CD8+T cells. In addition,
viral infections such as inﬂuenza and dengue virus signiﬁcantlyTable 1
Immune-Related Chemokines/Cytokines Released by Megakar-
yocytes.
Chemokine/Cytokine Function
Platelet Factor 4 Monocyte, neutrophil, lymphocyte recruitment
RANTES Anti-viral protein released from alpha granules
b-thromboglobulin Neutrophil recruitment and activation
Beta Defensin Antimicrobial protein released upon activation
Type I Interferon Cytokines released by megakaryocyte upon virial infection
| 96 | Educational Updates in Hematology Book | 2019; 3(S2)alter the transcriptome of megakaryocyte and platelets, resulting
in expression of novel anti-viral molecules such as interferon-
induced transmembrane 3 (IFITM3).21 Induction of IFITM3 in
megakaryocytes and surrounding hemopoietic stem cells reduces
viral infection and appear to be mediated through Type I
interferon release from the megakaryocyte.
Thrombin activates protease-activated receptors on platelets and
endothelial cells and generates ﬁbrin. Thrombin activation of
platelets results in release of chemokines and platelet microbicidal
proteins to reduce the spread of infection, while ﬁbrin formation
allows pathogens to be trapped and cleared by leukocytes.16,22,
∗23
Both reduced thrombin generation and enhanced ﬁbrinolysis in
mouse models increase susceptibility to bacterial infections, suggest-
ing thrombin, platelets and megakaryocytes play critical roles in
stemming the spread of infection, while maintaining hemostasis.24
The effect of pathogen-host interactions on
coagulation
Some intriguing observations suggest ﬁbrin formation in addition
to its role in ceasing bleeding, recruits macrophages (CD11/18) to
limit pathogens from spreading.25 For instance, streptococci
and staphylococci will invade the ﬁbrin and surroundings by
secreting strepto- and staphylokinase, which will activate matrix
metalloproteinases (MMPs) and plasmin to allow the penetration
of these pathogens (Fig. 1). Also, severe vascular damage may lead
to tissue hemorrhaging, which platelets resist, while hematomas
provide a growth media to the bacteria. Listeria sepsis in
immunocompromised patients underlines the importance of ﬁbrin
(ogen) in limiting the infection from spreading.26 Hantaviruses
trigger activation of ﬁbrinolysis in relation to coagulation activity,
simultaneously causing temporarily thrombocytopenia.27 Dengue
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penia through destruction of platelets and megakaryocytes.14,15,28
Inﬂuence of Inﬂammation on coagulation responses
As examples of inﬂammation, vasculitis and atherosclerosis both
impact the coagulation system. Immunological ANCA-vasculitis
activates both coagulation and ﬁbrinolysis, which associate with
impairment of renal function.29 In individuals with atherosclerosis
and impaired distal perfusion of leg arteries, the functional
severity of vascular disease relates to the levels of ﬁbrinogen,
thrombin-antithrombin complexes and D-dimer.30 Finally, in the
management of allogenic stem cell transplantation the outcome
and later graft-versus-host disease are affected by the early and
longitudinal maladapted regulation of coagulation.31,32 Thus,
reduced protein C activity and enhanced thrombin generation,
and high FVIII levels, refer to impaired protective effects of
endothelium during the transplantation recovery.
Future clinical perspectives
The main approach is to observe the symptoms and signs and
rapidly target the causative pathogen and individualize immune-
and supportive therapy, including thromboprophylaxis, to
eliminate the trigger of inﬂammation and coagulation disorder
(8). A stepwise laboratory follow-up alongside clinical hemostasis
abnormalities includes blood cell counts, C-reactive protein
assessing the extent of inﬂammation, antithrombin, ﬁbrinogen,
coagulation screening tests of prothrombin time (PT) and
activated partial thromboplastin time (APTT), thrombin time,
FVIII/VWF, and D-dimer will give a broad overall picture of the
potential deﬁciencies, over-activities (eg, ISTH DIC score), and
their tendencies upon active patient management and recovery.
Intravenous Vitamin K administration (1-5 mg, 0.15 mg being the
daily requirement) corrects PT (FII, FVII, FIX, FX, protein C and
S), if the liver synthesis is impaired due to consumption and poor
access to vitamin K limited by antibiotics and malabsorption.
Short APTT and thrombin time refer to enhanced contact
pathway and thrombin activity. The higher the ﬁbrinogen, the
poorer the ﬁbrinolytic capacity (D-dimer trends). FVIII/VWF
indicates the extent of endothelial damage and low antithrombin
may tilt the balance towards uncontrolled thrombin generation. In
the future, the global hemostasis assessment, including thrombin
generation capacity, will likely aid in the patient management.
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